Ranolazine 2HCl

InformationRanolazine 2HCl Ranolazine 2HCl (RS-43285) is a calcium uptake inhibitor via the sodium/calcium channal , used to treat chronic angina.In vitroRanolazine/xa0selectively inhibits/xa0late/xa0I(Na), reduces [Na(+)](i)-dependent calcium overload and attenuates the abnormalities of ventricular repolarisation and contractility that are associated with ischaemia/reperfusion and heart failure in myocardial cells. Ranolazine/xa0significantly and reversibly shortens the action potential duration (APD) of/xa0myocytes/xa0stimulated at either 0.5 Hz or 0.25 Hz in a concentration-dependent manner in left ventricular myocytes of dogs./xa0Ranolazine/xa0at 5 and 10 mM reversibly shortens the duration of twitch/xa0contractions/xa0(TC) and abolished the after/xa0contraction. Ranolazine/xa0is found to bind more tightly to the inactivated state than the resting state of the/xa0sodium/xa0channel underlying I(NaL).In vivoRanolazine/xa0(10 mM) significantly increases/xa0glucose/xa0oxidation/xa01.5-fold to 3-fold under conditions in which the contribution of/xa0glucoseto overall ATP production is low (low Ca, high FA, with insulin), high (high Ca, low Fa, with pacing), or intermediate in working/xa0hearts. Ranolazine/xa0similarly increases glucose/xa0oxidation in/xa0normoxic/xa0Langendorff/xa0hearts/xa0(high Ca, low FA; 15 mL/min). Ranolazine/xa0also significantly increases it during flow reduction to 7 mL/min, 3 mL/min, and 0.5 mL/min. Ranolazine/xa0significantly improves functional outcome, which is associated with significant increases in/xa0glucoseoxidation, a reversal of the increased FA/xa0oxidation/xa0seen in control reperfusions (versus preischemic), and a smaller but significant increase in glycolysis in/xa0reperfuse dischemic/xa0working/xa0hearts.Cell Datacell lines：Concentrations：Incubation Time：Powder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C24H33N3O4·2HCl Molecular Weight: 500.46